UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES
EXCHANGE ACT OF 1934
For the month
of August 2014
--------------
Commission File
Number: 001-32371
----------
SINOVAC BIOTECH
LTD.
No. 39 Shangdi
Xi Road
Haidian District
Beijing 100085,
People’s Republic of China
(Address of
principal executive offices)
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
SINOVAC BIOTECH
LTD. |
|
| |
| |
|
|
| |
By: | |
/s/
Weidong Yin |
|
| |
Name: |
|
Weidong Yin |
|
| |
Title: |
|
Chairman and Chief Executive Officer |
|
Date: August 19, 2014
Exhibit Index
Exhibit
99.1 – Press Release
Exhibit 99.2 – Press Release
Exhibit 99.3 – Press Release
Exhibit 99.1
Sinovac
Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
BEIJING, July 21,
2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced
today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled
syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB.
The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin
delivery in the coming months upon the demand.
Mr. Weidong Yin,
Chairman, President and CEO of Sinovac, commented, "We are pleased to have been selected again as the only supplier of the
inactivated hepatitis A vaccine in PFS presentation to the EPI in Beijing. With superior safety profile and proven efficacy, Healive
will continue to be administered to newborns using our easy-to-use, pre-filled syringes. We look forward to continuing to collaborate
with government agencies to control and prevent diseases with top-quality vaccines both in China and around the world."
Healive is the first
inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. Healive was launched by Sinovac
in 2002 and is currently available in adult and pediatric dosages. The hepatitis A vaccine has been included in China's national
immunization program since February 2008.
About Sinovac
Sinovac Biotech
Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization
of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. The Company filed a new drug
application for enterovirus 71 (against hand, foot and mouth disease) with China Food & Drug Administration. In 2009, Sinovac
was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the
Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1
pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including
vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella, and sIPV. Sinovac sells its vaccines mainly in China
and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize
seasonal flu vaccine in Mexico and hepatitis A vaccine in Chile.
Contact
Sinovac Biotech
Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
Exhibit 99.2
Sinovac
Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
BEIJING, July 23,
2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced
today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC") to be a supplier
of the seasonal influenza vaccine to the citizens of Beijing for 2014.
The Beijing CDC
plans to order a minimum of 1.2 million doses of the seasonal flu vaccine this year from four domestic vaccine manufacturers for
its vaccination campaign. Each manufacturer has agreed to supply no less than 300,000 doses. If required by the government, Sinovac
may deliver additional vaccines. The exact quantity of doses to be ordered will depend on demand during the flu season. In 2013,
Sinovac supplied approximately 400,000 doses of Anflu for the influenza vaccination campaign in Beijing. During last year's campaign,
the Beijing CDC administered a total of approximately 1.49 million doses for free to its target population. The Company expects
to begin delivering the vaccines in the third quarter of 2014.
Mr. Weidong Yin,
Chairman, President and CEO of Sinovac, commented, "We are pleased to be selected once again by the CDC to supply seasonal
flu vaccines for Beijing citizens. This vaccination campaign is an important step in protecting geriatric and school-age populations
from influenza."
The Beijing CDC
began purchasing seasonal flu vaccines in 2007 to prevent and control the spread of influenza among populations most susceptible
to complications from the virus. Each year, the Beijing CDC evaluates potential suppliers on product quality, service and price,
among other factors.
About Sinovac
Sinovac Biotech
Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization
of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. The Company filed a new drug
application for enterovirus 71 (against hand, foot and mouth disease) with China Food & Drug Administration. In 2009, Sinovac
was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the
Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1
pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including
vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella, and sIPV. Sinovac sells its vaccines mainly in China
and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize
seasonal flu vaccine in Mexico and hepatitis A vaccine in Chile.
Contact
Sinovac Biotech
Ltd.
Helen Yang / Chris
Lee
Tel: +86-10-8279-9659
/ 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
Exhibit 99.3
Sinovac
to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
BEIJING, July 25,
2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it
will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August
14, 2014 EDT. The Company will host a conference call prior to the market opening on Friday, August 15, 2014, at 8:00 a.m.
EDT (Friday, August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update
on recent corporate developments.
To access the conference
call, please dial 1-877-407-9039 (USA) or 1-201-689-8470 (International). A replay of the call will be available from 11
a.m. EDT on August 15, 2014, to August 29, 2014, at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517
(International) and reference the replay pin number 13587706.
A live audio webcast
of the call will also be available on the Investor Relations section of the Company’s website at www.sinovac.com. A webcast
replay will be available on the Company’s website for 30 days following the call, beginning August 15, 2014.
About Sinovac
Sinovac Biotech
Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization
of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against hepatitis
A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009,
Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese
Government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza
vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration
for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants
and children during its Phase III trial. The company is currently developing a number of new products including a Sabin-strain
inactivated polio vaccine, pneumococcal polysaccharides vaccine. pneumococcal conjugate vaccine and varicella vaccine. Sinovac
primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported
select vaccines to Mongolia, Nepal, the Philippines and Mexico, and was recently granted a license to commercialize its hepatitis
A vaccine in Chile. For more information, please visit the Company’s website at www.Sinovac.com .
Contact
Sinovac Biotech
Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024
